Cited 0 times in
Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장지은 | - |
dc.date.accessioned | 2022-01-26T01:57:04Z | - |
dc.date.available | 2022-01-26T01:57:04Z | - |
dc.date.issued | 2021-06 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187402 | - |
dc.description.abstract | Background: To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea. Methods: Patients aged ≥19 years who had received lenalidomide for the treatment of lower-risk, red blood cell (RBC) transfusion-dependent del(5q) MDS were selected. A filled case report form (CRF) with information from electronic medical records was requested from members of the acute myeloid leukemia (AML)/MDS Working Party of the Korean Society of Hematology. All the CRFs were gathered and analyzed. Results: A total of 31 patients were included in this study. Of 28 evaluable patients, 19 (67.9%) achieved RBC transfusion independence (RBC-TI). Female sex and the development of thrombocytopenia during treatment were associated with achieving RBC-TI. The most common non-hematologic toxicities were pruritus, fatigue, and rashes. All non-hematologic toxicities of grades ≥3 were limited to rash (12.9%) and pruritus (6.5%). Dose reduction was required in 15 of the 19 responders (78.9%). The most common final stable dosing schedule for the responders was 5 mg once every other day (31.6%). Conclusion: Lenalidomide efficacy and tolerability were similar in the Asian del(5q) MDS patients and western patients. Dose reduction during treatment was common, but it was not associated with inferior outcomes. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Korea Society of Hematology | - |
dc.relation.isPartOf | BLOOD RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Junshik Hong | - |
dc.contributor.googleauthor | Yoo Jin Lee | - |
dc.contributor.googleauthor | Sung Hwa Bae | - |
dc.contributor.googleauthor | Jun Ho Yi | - |
dc.contributor.googleauthor | Sungwoo Park | - |
dc.contributor.googleauthor | Myung Hee Chang | - |
dc.contributor.googleauthor | Young Hoon Park | - |
dc.contributor.googleauthor | Shin Young Hyun | - |
dc.contributor.googleauthor | Joo-Seop Chung | - |
dc.contributor.googleauthor | Ji Eun Jang | - |
dc.contributor.googleauthor | Joo Young Jung | - |
dc.contributor.googleauthor | So-Yeon Jeon | - |
dc.contributor.googleauthor | Seo-Young Song | - |
dc.contributor.googleauthor | Hawk Kim | - |
dc.contributor.googleauthor | Dae Sik Kim | - |
dc.contributor.googleauthor | Sung-Hyun Kim | - |
dc.contributor.googleauthor | Min Kyoung Kim | - |
dc.contributor.googleauthor | Sang Hoon Han | - |
dc.contributor.googleauthor | Seonyang Park | - |
dc.contributor.googleauthor | Yoo-Jin Kim | - |
dc.contributor.googleauthor | Je-Hwan Lee | - |
dc.identifier.doi | 10.5045/br.2021.2021086 | - |
dc.contributor.localId | A03477 | - |
dc.contributor.localId | A04381 | - |
dc.relation.journalcode | J00346 | - |
dc.identifier.eissn | 2288-0011 | - |
dc.identifier.pmid | 34187943 | - |
dc.subject.keyword | 5q deletion syndrome | - |
dc.subject.keyword | Anemia | - |
dc.subject.keyword | Lenalidomide | - |
dc.subject.keyword | Myelodysplastic syndrome | - |
dc.contributor.alternativeName | Jang, Ji Eun | - |
dc.contributor.affiliatedAuthor | 장지은 | - |
dc.citation.volume | 56 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 102 | - |
dc.citation.endPage | 108 | - |
dc.identifier.bibliographicCitation | BLOOD RESEARCH, Vol.56(2) : 102-108, 2021-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.